Publication:
Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy

Simple item page
dc.contributor.authorARIKAN, RUKİYE
dc.contributor.authorBAŞOĞLU TÜYLÜ, TUĞBA
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorYUMUK, PERRAN FULDEN
dc.contributor.authorKÖSTEK, OSMAN
dc.contributor.authorsAKIN TELLİ T., ÖZTÜRK M. S., Alan O., Hasanov R., KÖSTEK O., Arikan R., BAŞOĞLU TÜYLÜ T., Kaya S., Ercelep O., Babacan N. A., et al.
dc.date.accessioned2023-07-05T06:27:10Z
dc.date.available2023-07-05T06:27:10Z
dc.date.issued2022-07-01
dc.description.abstractObjective: The aim of this study was to investigate quality-of-life (QoL) in breast cancer (BC) patients treated with adjuvant endocrine therapy (AET). Methods: We designed a cross-sectional study of 233 BC patients treated with AET and used the Functional Assessment of Cancer Therapy - Breast questionnaire. Results: No significant difference was observed between endocrine agents. Duration of AET did not affect QoL. In the entire cohort, multivariate analysis determined age (p = 0.034) and switching treatment from tamoxifen to aromatase inhibitors (p = 0.049) as significant positive coefficients of QoL, while comorbidity (p = 0.072) tended to be associated with lower scores. Education level (p = 0.001) and chemotherapy (p = 0.04) were significant predictors of QoL in the tamoxifen group, while comorbidity (p = 0.04), surgery type (p = 0.02), radiotherapy (p = 0.006) and stage (p = 0.009) had a significant impact on QoL in aromatase inhibitors group. Conclusion: Evaluating the well-being of BC patients by QoL questionnaires is of great importance to identify particular subgroups that may require supportive care.
dc.identifier.citationAKIN TELLİ T., ÖZTÜRK M. S., Alan O., Hasanov R., KÖSTEK O., Arikan R., BAŞOĞLU TÜYLÜ T., Kaya S., Ercelep O., Babacan N. A., et al., "Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy", FUTURE ONCOLOGY, cilt.18, ss.2425-2439, 2022
dc.identifier.doi10.2217/fon-2021-1322
dc.identifier.endpage2439
dc.identifier.issn1479-6694
dc.identifier.startpage2425
dc.identifier.urihttps://hdl.handle.net/11424/290752
dc.identifier.volume18
dc.language.isoeng
dc.relation.ispartofFUTURE ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectONCOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectadjuvant endocrine therapy
dc.subjectbreast cancer
dc.subjectFACT-B
dc.subjectFACT-G
dc.subjectquality-of-life
dc.subjectFUNCTIONAL ASSESSMENT
dc.subjectPOSTMENOPAUSAL WOMEN
dc.subjectSYMPTOM BURDEN
dc.subjectTAMOXIFEN
dc.subjectSURVIVORS
dc.subjectEXEMESTANE
dc.subjectOUTCOMES
dc.subjectIMPACT
dc.subjectTRIAL
dc.titleReal-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy
dc.typearticle
dspace.entity.typePublication
local.avesis.idc01517b3-a595-421d-b6ba-2c3f1b150cad
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication22952072-1852-47c4-b1ff-669ac16d2ad6
relation.isAuthorOfPublicationddaeb928-6e68-4414-bd70-00515b6656a6
relation.isAuthorOfPublication059ce50a-8d16-4fc6-a86c-85c9baa19a5c
relation.isAuthorOfPublication4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa
relation.isAuthorOfPublication45c34df1-af1e-4065-bd94-a363edfac03a
relation.isAuthorOfPublication.latestForDiscovery22952072-1852-47c4-b1ff-669ac16d2ad6

Files

Collections

Research Outputs